RO 6927005

Drug Profile

RO 6927005

Alternative Names: RG-7787; RO-6927005

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Megakaryocyte potentiating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Jun 2016 Roche terminates phase I trial in Solid tumours in USA due to emerging risk benefit ratio (NCT02317419)
  • 28 Jul 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, Canada, Denmark and France (IV)
  • 01 Dec 2014 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, Canada, Denmark and France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top